Search
Larotrectinib
go.drugbank.com/drugs/DB14723ApprovedInvestigationalIt was notable for being the second tissue-agnostic chemotherapy ever approved by the FDA.[L4847]. On April 10, 2025, the FDA granted full drug approval.[L52805] … [L49821] Upon administration, larotrectinib binds to Trk, thereby preventing neurotrophin-Trk interaction and Trk activation, which results in both the induction of cellular apoptosis and the inhibition
Categories: Tropomyosin Receptor Kinases InhibitorsProducts: VITRAKVI®CÁPSULAS DE 100MGEletriptan
go.drugbank.com/drugs/DB00216ApprovedInvestigationalEletriptan is a second generation triptan drug developed by Pfizer Inc for the treatment of migraine headaches.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin Receptor AgonistsProducts: RELERTIsotretinoin
go.drugbank.com/drugs/DB00982ApprovedInvestigational[L6574] Isotretinoin is associated with major risks in pregnancy and is therefore only available under the iPLEDGE program in the United States. … [L6579] The first isotretinoin-containing product was FDA approved on 7 May 1982.[L6574]
Synonyms: (7E,9E,11E,13Z)-retinoic acidCinnamyl alcohol
go.drugbank.com/drugs/DB14186ApprovedCinnamyl alcohol has been shown to be a skin sensitizer, with a NOEL (No Effect Level) of ~4% [A34266]. Sensitivity to cinnamyl alcohol may be identified with a clinical patch test. … Due to the low levels found in cinnamon, cinnamyl alcohol is usually supplied as [DB14184] within commercial products.
Synonyms: (E)-cinnamyl alcohol, (2E)-3-phenylprop-2-en-1-olPegzilarginase
go.drugbank.com/drugs/DB14780Approved[L56053] By substituting the native manganese cofactor with cobalt to enhance catalytic activity, this agent effectively degrades elevated plasma arginine into ornithine and urea, thereby mitigating the … FDA in February 2026 for the treatment of hyperargininemia in adult and pediatric patients aged 2 years and older with ARG1-D, to be used in conjunction with dietary protein restriction.
Erdosteine
go.drugbank.com/drugs/DB05057ApprovedInvestigationalErdosteine has been shown to be safe and well tolerated in clinical trials. … Co-administration of erdosteine and amoxicillin in patients with acute infective exacerbation of chronic bronchitis resulted in higher concentrations of the antibiotic in the sputum, leading to earlier
Moroctocog alfa
go.drugbank.com/drugs/DB13999Approvedfibrinogen to fibrin, the fibrous protein that creates the scaffold of the clot. … Also known as Anti-Hemophilic Factor (AHF), endogenous Factor VIII is essential to the clotting process in the body due to its involvement in the clotting cascade where it is responsible for acting as
Products: REFACTO AF 500 IU IV ENJEKSIYONLUK COZELTI ICIN TOZ VE COZUC FLAKON, 1 ADET, REFACTO AF 250 IU IV ENJEKSIYONLUK COZELTI ICIN TOZ VE COZUCU FLAKON, 1 ADETMirvetuximab soravtansine
go.drugbank.com/drugs/DB12489ApprovedInvestigational[A254387] The antibody component of mirvetuximab soravtansine-gynx binds to FRα, a receptor overexpressed on the surface of epithelial tumor cells, characteristic of ovarian, endometrial, triple-negative … [A254382] After an ADC/receptor complex is formed, mirvetuximab soravtansine-gynx is internalized, and DM4 is released inside the cell.
Oteseconazole
go.drugbank.com/drugs/DB13055ApprovedInvestigational[A247035] This is possible thanks to the tetrazole moiety in oteseconazole that increases target selectivity. … [A247050] The use of oteseconazole is contraindicated in females of reproductive potential due to its embryo-fetal toxicity risks.[L41635] This drug was approved by the FDA on April 26, 2022.
Danicopan
go.drugbank.com/drugs/DB15401ApprovedInvestigational[A263501,L50417] Both hemolysis and thrombophilia are mediated primarily by the complement system.[A263501] Standard therapy for PNH involves the use of complement C5 inhibitors (e.g. … [A263506] It was subsequently approved by the FDA in March 2024.[L50386]